Can Lilly's Abemaciclib Overcome Third Place Finish In CDK4/6 Race?
Lilly reported positive top-line results for abemaciclib in the Phase III MONARCH 2 trial and revealed a regulatory strategy that has it rapidly racing after competing CDK4/6 inhibitors already approved for certain breast cancer patients.
You may also be interested in...
Lilly highlighted five prognostic factors at SABCS that may be linked to high Verzenio response. As the third CDK4/6 inhibitor on the US market, the company needs to differentiate its breast cancer drug from Pfizer's Ibrance and Novartis's Kisqali.
Lilly is cutting 3,500 jobs and may spin out or divest its animal health business to support pharma growth as sales of new medicines contributed significant revenue in the third quarter, but price increases were needed to offset falling demand for mature products.
While reporting 19% US sales growth for the quarter, Lilly also outlined a revised oncology R&D strategy and revealed that refiling the NDA for baricitinib may be delayed 18 months or more.